Zobrazeno 1 - 10
of 126
pro vyhledávání: '"Anisha B Patel"'
Autor:
Laura C Cappelli, Bernice Kwong, Jarushka Naidoo, Jonathan Leventhal, Mario E Lacouture, Meghan J Mooradian, Douglas B Johnson, Justine Cohen, Aparna Hegde, Steven T Chen, Riley Fadden, Leyre Zubiri, Shawn Kwatra, Ryan J Sullivan, Kerry L Reynolds, Allison Betof Warner, Yevgeniy R Semenov, Nicole R LeBoeuf, Krista M Rubin, Anna K Dewan, Alina Markova, Allireza Alloo, Daniel Q Bach, Amina Bougrine, Leeann Burton, Mariana Castells, Lauren Guggina, Victor Huang, Benjamin Kaffenberger, Daniela Kroshinsky, Cecilia Larocca, Jon McDunn, Jennifer Choi, Vinod Nambudiri, Caroline A Nelson, Anisha B Patel, Julia Pimkina, Johnathan Rine, Maxwell Sauder, Sheila Shaigany, Afreen Shariff
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 4 (2024)
With an increasing number of patients eligible for immune checkpoint inhibitors, the incidence of immune-related adverse events (irAEs) is on the rise. Dermatologic immune-related adverse events (D-irAEs) are the most common and earliest to manifest,
Externí odkaz:
https://doaj.org/article/0f9ad47d419c4ad4b3131ec90c49be9f
Publikováno v:
JMIR Dermatology, Vol 6, p e46620 (2023)
BackgroundAlternative bibliometrics or altmetrics, is a measure of an academic article’s impact on social media outlets, which is quantified by the Altmetric Attention score (AAS). Given a lack of data for altmetric trends during the COVID-19 pande
Externí odkaz:
https://doaj.org/article/f904773a78a041d080986effaa6ebcce
Publikováno v:
Journal of Immunotherapy and Precision Oncology, Pp 31-33 (2019)
Cutaneous mucinoses are a diverse group of diseases that are occasionally seen in the context of an adverse drug reaction. We report the case of a 59-year-old male who presented with an asymptomatic, acneiform rash on his forehead, scalp, nose, upper
Externí odkaz:
https://doaj.org/article/b891858608bf445d9d8047c39744908f
Publikováno v:
Journal of Immunotherapy and Precision Oncology, Pp 78-81 (2018)
Ipilimumab and nivolumab are human monoclonal antibodies used in cancer therapy. Ipilimumab targets cytotoxic T-lymphocyte-associated antigen and nivolumab acts against programmed death receptor-1. Both drugs have extensive side effect profiles with
Externí odkaz:
https://doaj.org/article/e6c11bc4c9ca43ad99b7ae32367f2b6a
Publikováno v:
Journal of Immunotherapy and Precision Oncology, Pp 82-84 (2018)
Pyoderma gangrenosum (PG) is an ulcerating neutrophilic dermatosis that is often associated with the underlying systemic disease. For example, PG is often a common presenting symptom in patients with hematologic malignancies, most commonly myelodyspl
Externí odkaz:
https://doaj.org/article/3f92cd82f8404240ad0ebbf7b523f371
Autor:
Padmavathi Karri, BS, Benjamin Freemyer, MD, Nader Aboul-Fettouh, MD, Anisha B. Patel, MD, Jonathan L. Curry, MD, Megan Rogge, MD
Publikováno v:
JAAD Case Reports, Vol 7, Iss , Pp 26-29 (2021)
Externí odkaz:
https://doaj.org/article/20e939c529794852bcc2af7c5ff1f512
Publikováno v:
Cancer Treatment and Research Communications, Vol 30, Iss , Pp 100506- (2022)
Immune checkpoint inhibitors and their associated immune-related cutaneous adverse events are continuing to become a mainstay of cancer treatment regimens. While most rashes are mild and easily manageable, severe or persistent rashes like lichenoid d
Externí odkaz:
https://doaj.org/article/450856a6995b46ec893e4937b8aa5895
Autor:
Elizabeth A. Dao, Saira J. George, Meghan M. Heberton, Omar Pacha, Craig A. Kovitz, Anisha B. Patel, Rhea M. Phillips
Publikováno v:
Cancer Treatment and Research Communications, Vol 32, Iss , Pp 100596- (2022)
Alpelisib is an alpha isoform-specific phosphatidylinositol 3-kinase (PI3K) inhibitor approved for use in the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor (HER2)-negative metastatic breast cancer in combination
Externí odkaz:
https://doaj.org/article/57706fab35ce41e3b986e7dc31f9d83e
Autor:
Michelle A. McNally, BSN, Ramya Vangipuram, MD, Matthew T. Campbell, MD, Priyadharsini Nagarajan, MD, PhD, Anisha B. Patel, MD, Jonathan L. Curry, MD, Meghan Heberton, MD
Publikováno v:
JAAD Case Reports, Vol 10, Iss , Pp 82-84 (2021)
Externí odkaz:
https://doaj.org/article/f296043fa8734222ac3cfd5179a26046
Autor:
Bora Lim, Angela Alexander, Jie S. Willey, Huiming Sun, Suyu Liu, Anisha B. Patel, Edwin Roger Parra, Cara Haymaker, Luisa Solis Soto, Alejandra Serrano, Baohua Sun, Cibelle Freitas Pinto Lima, Auriole Tamegnon, Renganayaki K. Pandurengan, Dzifa Douse, Jessica Lan, Luthra Raja, Randy Chu, Mark Knafl, Scott E. Woodman, Haifeng Zhu, Katja Shulze, Katherine Fedenko, Walter Darbonne, Naoto T. Ueno, Vicente Valero
Publikováno v:
Cancer Research. 83:P4-08
Background: Inflammatory breast cancer (IBC) is a rare but aggressive tumor type accounting for up to 10% of breast cancer deaths. One-third of IBCs express high PD-L1 that can be targeted by atezolizumab (Az). MEK inhibitor cobimetinib (Co) not only